Novo setback casts doubt on a new way to treat heart disease
Phase 3negativeZiltivekimabNegative
AI Analysis
Summary
Novo's ziltivekimab failed in a key Phase 3 trial for heart disease, triggering share sell-offs and raising concerns about other inflammation-targeting cardiovascular drugs in development at Novo and other biotechs.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Ziltivekimab failed in a key trial
Importance:8/10
Sentiment:
-0.85
cardiovascularinflammationtrial failurestock decline
Read the original article
Published by BioPharma Dive on July 31, 2026 4:11 PM